NCT00436605View on ClinicalTrials.gov

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

November 30, 2010

Conditions
Recurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Interventions
DRUG

dasatinib

Trial Locations (2)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00436605 - Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | Biotech Hunter | Biotech Hunter